Press "Enter" to skip to content

Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer

  • Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche’s atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as a first-line treatment for mPDAC. 
  • The study will enroll approximately 75 patients with a primary endpoint of disease control rate.
  •  The secondary endpoints include overall survival, progression-free survival (PFS), one-year survival, objective response rate, PFS at six months, duration of response, and toxicity profile. 
  • Novocure is the study sponsor, and Roche is providing atezolizumab for the trial.
  • Related: Novocure Presents Final Safety and Efficacy Results From Liver Cancer Trial.
  • Tumor Treating Fields are electric fields that disrupt cancer cell division.
  • Last week, the FDA granted breakthrough designation to the NovoTTF-200T System, TTFields, to be delivered together with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer.
  • Price Action: NVCR stock closed 1.74% lower at $129.53, while RHHBY closed at $46.31 on Monday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *